Novartis-partnered Matchpoint Therapeutics raises $150 million Series B to fund clinical entry

Matchpoint Therapeutics, a biotech company working with Novartis, announced the close of a new financing round. The round raised $150 million in Series B funding.

The capital will be used to advance the company’s lead drug candidate into first‑in‑human studies. Investors see the funding as a step toward clinical development.

The partnership with Novartis is expected to provide additional scientific and commercial support as the program moves forward. The financing reflects confidence in the company’s pipeline and its upcoming milestones.

The infusion of cash positions Matchpoint to begin clinical trials later this year, potentially accelerating its path toward market entry.